Bullous Pemphigoid

News

Dupixent is first FDA-approved drug for rare skin disease

The long list of therapeutic uses for Sanofi and Regeneron's Dupixent has been lengthened by an FDA approval for rare skin disease bullous pemphigoid.

News

Can Dupixent plug treatment gap in bullous pemphigoid?

The FDA is scheduled to deliver a verdict on Sanofi and Regeneron's Dupixent for rare autoimmune skin disorder bullous pemphigoid in June.

News

Dupixent delivers in two skin disease trials

Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications f

News

Akari begins late-stage trial of nomacopan for Bullous Pemph...

Akari Therapeutics is to begin a late-stage trial of nomacopan, its potential therapy for Bullous Pemphigoid, the rare autoimmune skin disorder.

Dupixent is first FDA-approved drug for rare skin disease

Can Dupixent plug treatment gap in bullous pemphigoid?

Dupixent delivers in two skin disease trials

Akari begins late-stage trial of nomacopan for Bullous Pemph...

Doctors dismayed by report of NHS AI proposal

Discover a new era of healthcare panel engagement: Grounded ...

Bullous Pemphigoid

Editor's Picks